FDA panel votes to expand use of Vertex cystic fibrosis drug

(Reuters) - A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said.

http://feedproxy.google.com/~r/reuters/healthNews/~3/IN0BDod2Wc0/story01.htm

Source: Reuters: Health - October 21, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

More News: Cystic Fibrosis | Food and Drug Administration (FDA) | Health